Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.
Identifying effective antivirals for treating Ebola virus disease (EVD) and minimizing transmission of such disease is critical. A variety of cell-based assays have been developed for evaluating compounds for activity against Ebola virus. However, very few reports discuss the variable assay conditio...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5864066?pdf=render |
| _version_ | 1830432327605420032 |
|---|---|
| author | Elena Postnikova Yu Cong Lisa Evans DeWald Julie Dyall Shuiqing Yu Brit J Hart Huanying Zhou Robin Gross James Logue Yingyun Cai Nicole Deiuliis Julia Michelotti Anna N Honko Richard S Bennett Michael R Holbrook Gene G Olinger Lisa E Hensley Peter B Jahrling |
| author_facet | Elena Postnikova Yu Cong Lisa Evans DeWald Julie Dyall Shuiqing Yu Brit J Hart Huanying Zhou Robin Gross James Logue Yingyun Cai Nicole Deiuliis Julia Michelotti Anna N Honko Richard S Bennett Michael R Holbrook Gene G Olinger Lisa E Hensley Peter B Jahrling |
| author_sort | Elena Postnikova |
| collection | DOAJ |
| description | Identifying effective antivirals for treating Ebola virus disease (EVD) and minimizing transmission of such disease is critical. A variety of cell-based assays have been developed for evaluating compounds for activity against Ebola virus. However, very few reports discuss the variable assay conditions that can affect the results obtained from these drug screens. Here, we describe variable conditions tested during the development of our cell-based drug screen assays designed to identify compounds with anti-Ebola virus activity using established cell lines and human primary cells. The effect of multiple assay readouts and variable assay conditions, including virus input, time of infection, and the cell passage number, were compared, and the impact on the effective concentration for 50% and/ or 90% inhibition (EC50, EC90) was evaluated using the FDA-approved compound, toremifene citrate. In these studies, we show that altering cell-based assay conditions can have an impact on apparent drug potency as measured by the EC50. These results further support the importance of developing standard operating procedures for generating reliable and reproducible in vitro data sets for potential antivirals. |
| first_indexed | 2024-12-21T02:22:04Z |
| format | Article |
| id | doaj.art-b7073771bcb34e73930d7a2a00ff3b23 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T02:22:04Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b7073771bcb34e73930d7a2a00ff3b232022-12-21T19:19:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019488010.1371/journal.pone.0194880Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.Elena PostnikovaYu CongLisa Evans DeWaldJulie DyallShuiqing YuBrit J HartHuanying ZhouRobin GrossJames LogueYingyun CaiNicole DeiuliisJulia MichelottiAnna N HonkoRichard S BennettMichael R HolbrookGene G OlingerLisa E HensleyPeter B JahrlingIdentifying effective antivirals for treating Ebola virus disease (EVD) and minimizing transmission of such disease is critical. A variety of cell-based assays have been developed for evaluating compounds for activity against Ebola virus. However, very few reports discuss the variable assay conditions that can affect the results obtained from these drug screens. Here, we describe variable conditions tested during the development of our cell-based drug screen assays designed to identify compounds with anti-Ebola virus activity using established cell lines and human primary cells. The effect of multiple assay readouts and variable assay conditions, including virus input, time of infection, and the cell passage number, were compared, and the impact on the effective concentration for 50% and/ or 90% inhibition (EC50, EC90) was evaluated using the FDA-approved compound, toremifene citrate. In these studies, we show that altering cell-based assay conditions can have an impact on apparent drug potency as measured by the EC50. These results further support the importance of developing standard operating procedures for generating reliable and reproducible in vitro data sets for potential antivirals.http://europepmc.org/articles/PMC5864066?pdf=render |
| spellingShingle | Elena Postnikova Yu Cong Lisa Evans DeWald Julie Dyall Shuiqing Yu Brit J Hart Huanying Zhou Robin Gross James Logue Yingyun Cai Nicole Deiuliis Julia Michelotti Anna N Honko Richard S Bennett Michael R Holbrook Gene G Olinger Lisa E Hensley Peter B Jahrling Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS ONE |
| title | Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. |
| title_full | Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. |
| title_fullStr | Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. |
| title_full_unstemmed | Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. |
| title_short | Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. |
| title_sort | testing therapeutics in cell based assays factors that influence the apparent potency of drugs |
| url | http://europepmc.org/articles/PMC5864066?pdf=render |
| work_keys_str_mv | AT elenapostnikova testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT yucong testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT lisaevansdewald testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT juliedyall testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT shuiqingyu testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT britjhart testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT huanyingzhou testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT robingross testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT jameslogue testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT yingyuncai testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT nicoledeiuliis testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT juliamichelotti testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT annanhonko testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT richardsbennett testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT michaelrholbrook testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT genegolinger testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT lisaehensley testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs AT peterbjahrling testingtherapeuticsincellbasedassaysfactorsthatinfluencetheapparentpotencyofdrugs |